amlodipine 5 MG / hydrochlorothiazide 12.5 MG / olmesartan medoxomil 20 MG Oral Tablet
amlodipine
RxCUI: 999967
What the CMS Formulary Data Shows for amlodipine 5 MG / hydrochlorothiazide 12.5 MG / olmesartan medoxomil 20 MG Oral Tablet
Per the CMS 2026 Part D formulary file, amlodipine 5 MG / hydrochlorothiazide 12.5 MG / olmesartan medoxomil 20 MG Oral Tablet (RxNorm concept RXCUI 999967, generic name amlodipine) appears on 243 distinct formulary files spanning 4,415 Medicare Part D plan offerings - 87.1% of enrollable Part D products, near-universal placement. Tier placement ranges from Tier 1 to Tier 6, with a cross-plan average of Tier 2.5.
Real-world access to amlodipine 5 MG / hydrochlorothiazide 12.5 MG / olmesartan medoxomil 20 MG Oral Tablet depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 54.7% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 11,575,402 Part D beneficiaries filled amlodipine 5 MG / hydrochlorothiazide 12.5 MG / olmesartan medoxomil 20 MG Oral Tablet in 2023, with total plan-and-beneficiary spending of $407,233,375 and an average per-beneficiary annual cost of $35.18. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry amlodipine 5 MG / hydrochlorothiazide 12.5 MG / olmesartan medoxomil 20 MG Oral Tablet today.
Coverage Details
- Formularies covering
- 243
- Plans covering
- 4,415
- Coverage rate
- 87.1%
- Tier range
- Tier 1 – Tier 6
- Average tier
- Tier 2, Generic
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 54.7% of formularies
2023 Medicare Spending
- Beneficiaries
- 11,575,402
- Total spending
- $407,233,375
- Avg per beneficiary
- $35.18
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering amlodipine 5 MG / hydrochlorothiazide 12.5 MG / olmesartan medoxomil 20 MG Oral Tablet
100 Medicare Advantage plans with Part D drug coverage include this drug.
Frequently Asked Questions
Is amlodipine 5 MG / hydrochlorothiazide 12.5 MG / olmesartan medoxomil 20 MG Oral Tablet covered by Medicare Part D?
Yes, amlodipine 5 MG / hydrochlorothiazide 12.5 MG / olmesartan medoxomil 20 MG Oral Tablet is covered by 4,415 Medicare Part D plans (87.1% of all Part D formularies).
What tier is amlodipine 5 MG / hydrochlorothiazide 12.5 MG / olmesartan medoxomil 20 MG Oral Tablet on Medicare Part D plans?
amlodipine 5 MG / hydrochlorothiazide 12.5 MG / olmesartan medoxomil 20 MG Oral Tablet averages Tier 2.5 across Part D plans, ranging from Tier 1 to Tier 6.
Does amlodipine 5 MG / hydrochlorothiazide 12.5 MG / olmesartan medoxomil 20 MG Oral Tablet require prior authorization?
0% of Part D formularies require prior authorization for amlodipine 5 MG / hydrochlorothiazide 12.5 MG / olmesartan medoxomil 20 MG Oral Tablet. Step therapy: 0%. Quantity limits: 54.7%.
How much does Medicare spend on amlodipine 5 MG / hydrochlorothiazide 12.5 MG / olmesartan medoxomil 20 MG Oral Tablet?
In 2023, total Medicare Part D spending on amlodipine 5 MG / hydrochlorothiazide 12.5 MG / olmesartan medoxomil 20 MG Oral Tablet was $407,233,375, covering 11,575,402 beneficiaries. The average spend per beneficiary was $35.18.
Read our methodology - how this data is sourced, computed, and verified.